Adn-388 - |work|

: Like tirzepatide (Zepbound), it activates both the Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP) receptors to suppress appetite and enhance insulin secretion.

As of early 2026, CT-388 has demonstrated some of the highest weight-loss percentages recorded in the incretin class. ADN-388

-arrestin causes receptors to "internalize" or become desensitized over time. By avoiding this, CT-388 aims for prolonged pharmacological activity and potentially more durable weight loss. : Like tirzepatide (Zepbound), it activates both the

is a potent investigational weight-loss drug currently in Phase III clinical development. Developed by Roche and its subsidiary Genentech, this once-weekly subcutaneous injection belongs to the "incretin mimetic" class, similar to popular medications like Wegovy and Zepbound. Core Mechanism: How CT-388 Works By avoiding this, CT-388 aims for prolonged pharmacological

CT-388 is a dual GLP-1/GIP receptor agonist, meaning it targets two different hormone receptors to regulate metabolism. Its unique "signal-biased" design sets it apart from existing therapies:

As of early 2026, CT-388 has demonstrated some of the highest weight-loss percentages recorded in the incretin class.

-arrestin causes receptors to "internalize" or become desensitized over time. By avoiding this, CT-388 aims for prolonged pharmacological activity and potentially more durable weight loss.

CT-388 is a dual GLP-1/GIP receptor agonist, meaning it targets two different hormone receptors to regulate metabolism. Its unique "signal-biased" design sets it apart from existing therapies: